Original Study| Volume 15, ISSUE 6, e995-e999, December 2017

Racial Variation in the Outcome of Subsequent Prostate Biopsies in Men With an Initial Diagnosis of Atypical Small Acinar Proliferation

Published:April 25, 2017DOI:



      African American (AA) men are known to have more aggressive prostate cancer (PCa) compared with Caucasian American men. We sought to determine predictors of subsequent detection and risk stratification of PCa in a racially diverse group of men with atypical small acinar proliferation (ASAP) on initial prostate biopsy.

      Materials and Methods

      A retrospective analysis was conducted on data from men with ASAP on initial prostate biopsy who subsequently received confirmatory biopsies between September 2000 and July 2015. Biopsies with more than 3 years between initial and confirmatory biopsies were excluded. Race, age, body mass index, transrectal ultrasound volume, serum prostate-specific antigen (PSA), PSA velocity, PSA density, and elapsed time between biopsies were assessed for predictive value in subsequent PCa diagnosis after an initial finding of ASAP.


      Of 106 men analyzed, 75 (71%) were AA and 31 (29%) were non-AA. Baseline variables revealed AA men had higher PSA levels, PSA velocity, and PSA density (all P < .05). PCa was diagnosed in subsequent biopsy in 42 (40%) patients without significant racial variation; 30 (40%) AA versus 12 (39%) non-AA. Of the 42 PCa patients, 25 (24%) met Epstein criteria for significant disease without racial variation; 18 (24%) AA versus 7 (23%) non-AA. Only 10 (9%) patients had any component of Gleason 4; 7 (9%) AA versus 3 (10%) non-AA. In multivariate analysis, increasing age, PSA level, and PSA density were significant predictors of PCa.


      AA men diagnosed with ASAP on initial prostate biopsy do not have increased risk of PCa on confirmatory biopsy compared with non-AA men.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cook M.B.
        • Rosenberg P.S.
        • McCarty F.A.
        • et al.
        Racial disparities in prostate cancer incidence rates by census division in the United States, 1999-2008.
        Prostate. 2015; 75: 758-763
        • Peters N.
        • Armstrong K.
        Racial differences in prostate cancer treatment outcomes: a systematic review.
        Cancer Nurs. 2005; 28: 108-118
        • Daskivich T.J.
        • Kwan L.
        • Dash A.
        • Litwin M.S.
        Racial parity in tumor burden, treatment choice and survival outcomes in men with prostate cancer in the VA healthcare system.
        Prostate Cancer Prostatic Dis. 2015; 18: 104-109
        • Moses K.A.
        • Paciorek A.T.
        • Penson D.F.
        • Carroll P.R.
        • Master V.A.
        Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE.
        J Clin Oncol. 2010; 28: 1069-1074
        • Rebbeck T.R.
        • Haas G.P.
        Temporal trends and racial disparities in global prostate cancer prevalence.
        Can J Urol. 2014; 21: 7496-7506
        • Epstein J.I.
        • Herawi M.
        Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care.
        J Urol. 2006; 175: 820-834
        • Leone A.
        • Rotker K.
        • Butler C.
        • et al.
        Atypical small acinar proliferation: repeat biopsy and detection of high grade prostate cancer.
        Prostate Cancer. 2015; 2015: 810159
        • Montironi R.
        • Scattoni V.
        • Mazzucchelli R.
        • Lopez-Beltran A.
        • Bostwick D.G.
        • Montorsi F.
        Atypical foci suspicious but not diagnostic of malignancy in prostate needle biopsies (also referred to as “atypical small acinar proliferation suspicious for but not diagnostic of malignancy”).
        Eur Urol. 2006; 50: 666-674
        • Leone L.
        • Lacetera V.
        • Montironi R.
        • et al.
        Biopsy follow-up in patients with isolated atypical small acinar proliferation (ASAP) in prostate biopsy.
        Arch Ital Urol Androl. 2014; 86: 332-335
        • Carroll P.R.
        • Parsons J.K.
        • Andriole G.
        • et al.
        Prostate cancer early detection, version 2.2015.
        J Natl Compr Canc Netw. 2015; 13: 1534-1561
        • Kopp R.P.
        • Parsons J.K.
        • Shiau J.
        • et al.
        Prostate atypia: clinical and pathological variables associated with cancer diagnosis on repeat biopsy.
        Prostate Cancer Prostatic Dis. 2011; 14: 149-154
        • Epstein J.I.
        • Walsh P.C.
        • Carmichael M.
        • Brendler C.B.
        Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
        JAMA. 1994; 271: 368-374
        • Leone A.
        • Gershman B.
        • Rotker K.
        • et al.
        Atypical small acinar proliferation (ASAP): is a repeat biopsy necessary ASAP? A multi-institutional review.
        Prostate Cancer Prostatic Dis. 2016; 19: 68-71
        • Warlick C.
        • Feia K.
        • Tomasini J.
        • Iwamoto C.
        • Lindgren B.
        • Risk M.
        Rate of Gleason 7 or higher prostate cancer on repeat biopsy after a diagnosis of atypical small acinar proliferation.
        Prostate Cancer Prostatic Dis. 2015; 18: 255-259
        • San Francisco I.F.
        • Werner L.
        • Regan M.M.
        • Garnick M.B.
        • Bubley G.
        • DeWolf W.C.
        Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.
        J Urol. 2011; 185: 471-476
        • Oh J.J.
        • Hong S.K.
        • Lee J.K.
        • et al.
        Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
        BJU Int. 2012; 110: E494-E499
        • Kim T.S.
        • Ko K.J.
        • Shin S.J.
        • et al.
        Multiple cores of high grade prostatic intraepithelial neoplasia and any core of atypia on first biopsy are significant predictor for cancer detection at a repeat biopsy.
        Korean J Urol. 2015; 56: 796-802
        • Siddiqui M.M.
        • Rais-Bahrami S.
        • Turkbey B.
        • et al.
        Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.
        JAMA. 2015; 313: 390-397
        • Tanase C.P.
        • Codrici E.
        • Popescu I.D.
        • et al.
        Prostate cancer proteomics: current trends and future perspectives for biomarker discovery.
        Oncotarget. 2017; 8: 18497-18512
        • Partin A.W.
        • Van Neste L.
        • Klein E.A.
        • et al.
        Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies.
        J Urol. 2014; 192: 1081-1087
        • Stewart G.D.
        • Van Neste L.
        • Delvenne P.
        • et al.
        Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study.
        J Urol. 2013; 189: 1110-1116